Is SNDX or SNY more undervalued in 2026?

CirclFi compares Syndax Pharmaceuticals, Inc. (SNDX) and Sanofi (SNY) using 13 institutional-grade valuation models. SNDX has a Quality of Company score of 5.7/10 while SNY scores 7.3/10.

Which is a better buy — SNDX or SNY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SNDX and SNY valuations compare?

SNDX at $19.59 and SNY at $43.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SNDX vs SNY Valuation Comparison 2026 — Intrinsic Value Analysis

SNDX

Pharmaceutical Preparations

Syndax Pharmaceuticals, Inc.

Quality

5.7

out of 10

Value Trap

LOW

Price

$19.59

Last close

Models

9/13

Active

SNY

Pharmaceutical Preparations

Sanofi

Quality

7.3

out of 10

Value Trap

SAFE

Price

$43.67

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	SNDX Fair Value	SNDX Upside	SNY Fair Value	SNY Upside
Bayesian DCF	Intrinsic	$1.11	-94.3%	$81.10	+85.7%
Earnings Power Value	Intrinsic	$2.58	-87.9%	$30.11	-31.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SNDX vs SNY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SNDX vs SNY — Which Stock Is More Undervalued?

SNY scores higher with a 7.3/10 quality rating vs SNDX's 5.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Syndax Pharmaceuticals, Inc. (SNDX) and Sanofi (SNY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SNDX currently trades at $19.59 with a QOC of 5.7/10, while SNY trades at $43.67 with a QOC of 7.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).